Filing Details
- Accession Number:
- 0001140361-14-043317
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-24 19:32:21
- Reporting Period:
- 2014-11-21
- Filing Date:
- 2014-11-24
- Accepted Time:
- 2014-11-24 19:32:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1594337 | Corium International Inc. | CORI | Pharmaceutical Preparations (2834) | 383230774 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1241009 | S Robert Breuil | C/O Corium International, Inc. 235 Constitution Drive Menlo Park CA 94025 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-11-21 | 3,000 | $5.37 | 4,000 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2014-11-24 | 1,600 | $5.40 | 5,600 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- Represents the aggregate of purchases effected on the same day at different prices.
- Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $5.345 to $5.39. Full information regarding the number of shares purchased at each price shall be provided, upon written request, to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- Includes 1,000 shares acquired under the Issuer's employee stock purchase plan on November 19, 2014.
- Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $5.33 to $5.55. Full information regarding the number of shares purchased at each price shall be provided, upon written request, to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.